- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04640636
IM Ketamine vs Midazolam for Suicidal ER Patients
August 8, 2023 updated by: Michael Grunebaum, MD, New York State Psychiatric Institute
Rising US suicide rates and the increased risk of suicide among persons who visit an emergency department (ED) for suicidality make the ED an important site for interventions to prevent suicide.
There is no approved treatment for rapid relief of suicidal thoughts although clinical trials, including ours, show relief of suicidal thoughts within hours of treatment with inexpensive, generic, sub-anesthetic ketamine.
We propose a clinical trial of intramuscular ketamine in depressed ED patients with high-risk suicidality, which if successful would support a novel, easy-to-use, scalable intervention for busy emergency clinicians to implement.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
Rising US suicide rates and the increased risk of suicide among persons who visit an emergency department (ED) for suicidality make the ED an important site for interventions to prevent suicide.
Clinical trials, including ours, show relief of suicidal thoughts within hours of treatment with inexpensive, generic, subanesthetic ketamine.
We have received NIMH R01 funding to conduct a clinical trial of intramuscular (IM) ketamine in unipolar or bipolar depressed adults who present to the CUIMC psychiatric ED with suicidality severe enough to require inpatient hospitalization as judged by ED clinical staff.
Clinical staff will ask potentially eligible patients if they would like to learn more about the study, and if so, a research assistant (RA) will describe the study to the patient and perform a basic eligibility screen.
Key exclusions are unstable medical problems, substance abuse, psychosis, and further detail is provided in the Inclusion/Exclusion criteria.
Participants (N=90) who enroll will undergo baseline clinical ratings, brief cognitive testing, and then be randomized, double-blind, in a 2:1 ratio to a single IM injection of ketamine (n=60) or midazolam comparator (n=30).
Vital signs and clinical state will be monitored until injection effects subside (approximately 2 hrs).
Blood samples will be drawn at 60 minutes and 90 minutes postinjection to assay ketamine level and a genetic sample will be stored.
All participants will then be admitted to the 9GN inpatient unit for standard clinical treatment with periodic research follow-up ratings through 4 weeks post-discharge from hospital.
Ongoing outpatient treatment will be arranged by the inpatient clinical team.
Positive results from this trial would support a novel, easy-to-use, inexpensive, and scalable intervention for busy emergency clinicians to implement.
Study Type
Interventional
Enrollment (Estimated)
90
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael Grunebaum, MD
- Phone Number: 646-774-7573
- Email: michael.grunebaum@nyspi.columbia.edu
Study Contact Backup
- Name: Sumra Sajid, BA
- Phone Number: 646-774-7564
- Email: sumra.sajid@nyspi.columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Comprehensive Psychiatric Emergency Department of Columbia University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- DSM5 unipolar or bipolar (I, II, or Unspecified) major depressive episode
- Presenting to emergency department and assessed by psychiatrist staff as needing inpatient treatment due to suicidality
- Participant agrees to voluntary inpatient psychiatric admission
- Beck Scale for Suicidal Ideation score of 4 or higher
Exclusion Criteria:
- Substance use disorder in past 2 weeks
- Current psychosis or mania
- Intellectual disability
- Inadequate understanding of English and/or lack of capacity for informed consent
- Pregnancy or lactation
- Medical contraindication to ketamine or midazolam
- Unstable medical or neurological illness such as uncontrolled hypertension, significant cardiac arrhythmia, unstable cerebrovascular disease. Chronic, stable medical conditions such as controlled hypertension or diabetes will not be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ketamine
Ketamine hydrochloride 0.5 mg/kg IM single injection
|
single IM injection of ketamine hydrochloride 0.5 mg/kg
|
Active Comparator: midazolam
Midazolam 0.06 mg/kg IM single injection
|
single IM injection of midazolam 0.06 mg/kg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Scale for Suicidal Ideation (SSI)
Time Frame: 24 hours post-treatment
|
Beck Scale for Suicidal Ideation clinician-rated version
|
24 hours post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systematic Assessment for Treatment Emergent Events (SAFTEE)
Time Frame: 24 hours post-treatment
|
Frequency of adverse events at 24 hours post-treatment
|
24 hours post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Michael Grunebaum, MD, New York State Psychiatric Institute/Columbia University Irving Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 2, 2021
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
March 1, 2025
Study Registration Dates
First Submitted
November 20, 2020
First Submitted That Met QC Criteria
November 20, 2020
First Posted (Actual)
November 23, 2020
Study Record Updates
Last Update Posted (Actual)
August 9, 2023
Last Update Submitted That Met QC Criteria
August 8, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Bipolar and Related Disorders
- Self-Injurious Behavior
- Suicide
- Depression
- Depressive Disorder
- Bipolar Disorder
- Suicidal Ideation
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Ketamine
- Midazolam
Other Study ID Numbers
- 8070 (CTEP)
- R01MH125155-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All associated research findings published or provided to NIH, will be made readily available for research purposes to qualified individuals within the scientific community.
All data will be made anonymous and available after written requests for data are submitted by such qualified individuals to the PI.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Suicidal Ideation
-
University of WashingtonUnited States Department of Defense; Military Suicide Research ConsortiumCompletedSuicidal and Self-injurious Behavior | Suicidal Ideation ActiveUnited States
-
The Catholic University of AmericaUniversity of Washington; VA Office of Research and DevelopmentCompletedSuicidal and Self-injurious Behavior | Suicidal Ideation Active
-
Emory UniversityGeorgia Institute of TechnologyCompletedSuicide, Suicidal IdeationUnited States
-
Henry M. Jackson Foundation for the Advancement...University of Pennsylvania; University of Michigan; Duke University; US Department... and other collaboratorsUnknownSuicide, Attempted | Suicidal Ideation ActiveUnited States
-
Technische Universität DresdenUnknownDepression | Suicidal Ideation/BehaviorGermany
-
International Islamic University, IslamabadRecruitingImpulsivity | Suicidal Ideation and BehaviorPakistan
-
VA Office of Research and DevelopmentCentral Texas Veterans Health Care SystemRecruitingHealth | Reintegration Difficulties | Suicidal Ideation and Behaviors | ConnectednessUnited States
-
Children's Hospital Medical Center, CincinnatiCompleted
-
Eisenhower Army Medical CenterAugusta University; The Geneva Foundation; Congressionally Directed Medical Research...CompletedSuicidal Ideation | Suicide | Suicidal Intention | Suicidal Impulses | Suicidal and Self-Injurious Behavior | Suicidal DepressionUnited States
-
Ohio State UniversityUniversity of Minnesota; Rutgers UniversityCompletedSuicidal Ideation | SuicidalUnited States
Clinical Trials on Ketamine hydrochloride injection
-
Juvenile Bipolar Research FoundationTerminatedBipolar DisorderUnited States
-
Haihe Biopharma Co., Ltd.Shanghai Institute of Materia Medica, Chinese Academy of SciencesCompletedAdvanced Solid TumorChina
-
Ciusss de L'Est de l'Île de MontréalRecruiting
-
Xianhai MaoChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHepatocellular Carcinoma | Adjuvant TherapyChina
-
Tianjin Medical University General HospitalRecruitingPostoperative Pain | Postoperative Cognitive DysfunctionChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruiting
-
Isfahan University of Medical SciencesUnknownProcedural SedationIran, Islamic Republic of
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Integrative Psychiatry InstituteNot yet recruitingPsychedelic Experiences | Therapeutic Alliance | Psychology, Perceptual